C-List and Commercial Catalog Masterclass: PBM CEO Panel
Two senior commercial insurance leaders share candid views on China’s evolving market—what’s working, where integration lags, and if the new commercial innovative drug list could help close gaps and drive future growth.
Not yet a member?
Access360 membership provides structured intelligence on China’s evolving health policy, coverage, and financing system, with member briefings, archive access, and opportunities to submit questions on published analyses.
Explore Membership